Letairis and Rifadin IV Intravenous

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Blood levels and effects of ambrisentan may increase during the first few days of treatment with rifAMPin. This can increase the risk of serious side effects such as liver damage, anemia, and fluid accumulation (particularly in the lungs). You may need more frequent monitoring by your doctor for several days if you have been using ambrisentan and are starting treatment with rifAMPin. Contact your doctor immediately if you experience fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Also seek medical attention if you develop paleness, dizziness, fainting, swelling, unusual weight gain, difficulty breathing, and/or shortness of breath. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Acute, but not long-term, coadministration of rifampin increases the plasma concentrations of ambrisentan. Rifampin is an inhibitor of organic anion transporting polypeptide (OATP), a strong inducer of CYP450 3A4 and 2C19, and an inducer of P-glycoprotein and uridine diphosphate glucuronosyltransferases (UGTs), all of which have been shown in vitro to be involved in the metabolic clearance of ambrisentan. In healthy volunteers, acute coadministration (3 days) of rifampin 600 mg once daily with ambrisentan 10 mg once daily was associated with a transient 2-fold increase in ambrisentan systemic exposure (AUC). However, by day 7, rifampin had no clinically relevant effect on the AUC or Cmax of ambrisentan.

MANAGEMENT: Patients receiving ambrisentan therapy should be closely monitored when starting treatment with rifampin. Because ambrisentan is associated with dose-related hepatotoxicity, patients should be advised to notify their physician if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Patients should also be monitored for anemia, fluid retention, and pulmonary edema.

Letairis

Generic Name: ambrisentan

Brand name: Letairis

Synonyms: n.a.

What is Letairis?

Rifadin IV Intravenous

Generic Name: rifampin

Brand name: Rifadin IV, Rifadin, Rimactane

Synonyms: Rifadin IV (Intravenous), Rifadin IV

What is Rifadin IV Intravenous?